Abbott bolsters diagnostics portfolio with up to $23 billion buyout of Exact Sciences

Abbott will acquire cancer-test maker Exact Sciences in an up-to-$23 billion cash deal that pays $105 per share, a roughly 21.8% premium, bringing Exact’s flagship colorectal-screening test Cologuard into Abbott’s diagnostics portfolio. The transaction—one of Abbott’s largest in nearly a decade and its first major push into preventive cancer screening—aims to help offset revenue declines from Covid-19 testing kits. Exact shares jumped more than 17% premarket while Abbott fell nearly 2%; the deal is expected to close in Q2 2026 pending shareholder approval.

Analysis

Abbott announced an up-to-$23 billion all-cash agreement to acquire Exact Sciences for $105 per share, a roughly 21.8% premium to the last close, bringing Exact's flagship colorectal-screening test Cologuard into Abbott's diagnostics portfolio. The deal is described as one of Abbott's largest in nearly a decade and represents its first major push into preventive cancer screening, explicitly positioned to help offset revenue declines from its Covid-19 testing kits.

Market reaction was immediate: Exact shares rose more than 17% in premarket trading while Abbott shares fell nearly 2%, reflecting a near-term revaluation of both acquirer and target and signaling investor uncertainty about deal execution and near-term impact on Abbott. The transaction is expected to close in the second quarter of 2026 pending Exact shareholder approval, creating a nearly two-year window of execution and approval risk.

Strategically, the acquisition materially diversifies Abbott's diagnostics mix by adding a preventive oncology product with established market presence, which could stabilize diagnostics revenue if integration succeeds. Key near-term monitoring points for investors are shareholder approval, the cadence of disclosed synergies and integration plans, and any subsequent information on how Abbott will finance or account for the acquisition when evaluating margin and capital allocation implications.

Key Decisions for Investors

• Consider hedging or trimming near-term Abbott exposure given the ~2% share decline and execution/timing risk while awaiting financing and synergy disclosures
• Exact shareholders should assess the $105 cash offer as a liquidity event and weigh tendering against the 21.8% premium and the Q2 2026 closing timeline
• Arbitrage-oriented investors may consider a risk-priced merger-arbitrage position but only after modeling shareholder approval probability and the nearly two-year closing window
• Monitor upcoming disclosures on integration plans and diagnostics revenue trajectory to judge whether the Cologuard acquisition will credibly offset Covid-19 testing declines and justify a change in position